PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 29, 2026JCO Global Oncology0 citationsOpen Access

Primary Platinum-Resistant Ovarian Cancer: Clinicopathologic Correlates and Outcomes From a Multicenter Prospective Indian Registry

View Full Paper
ASAmit SehrawatLSLakhwinder SinghDSDeepak Sundriyal

Key Points

  • This research aims to identify factors linked to primary platinum-resistant ovarian cancer and assess survival outcomes among patients.
  • Data analyzed from a multicenter prospective registry involving six tertiary care centers in India from January 2022 to December 2023.
  • Evaluated demographic, clinical, and treatment variables in women diagnosed with epithelial ovarian cancer.
  • Survival outcomes were measured over a median follow-up of 10.32 months.
  • Of 367 women with newly diagnosed ovarian cancer, 62 (16.9%) had primary platinum-resistant ovarian cancer.
  • Median progression-free survival was 4.75 months (95% CI, 4 to 6) and overall survival was 9.33 months (95% CI, 6.2 to 16.3).
  • Primary platinum resistance was associated with factors like poor performance status, advanced stage, and omission of debulking surgery (P < .05).

Abstract

PURPOSE To identify clinicopathologic factors associated with primary platinum-resistant ovarian cancer and evaluate survival outcomes using data from a multicenter, prospectively maintained Indian cancer registry. MATERIALS AND METHODS Data were analyzed from a prospective database of Network of Oncology Clinical Trials in India registry from six tertiary care centers between January 2022 and December 2023. Primary platinum-resistant ovarian cancer was defined as progression during treatment or recurrence within 6 months of completing initial platinum-based chemotherapy. Demographic, clinical, and treatment variables along with survival outcomes were evaluated. RESULTS Among 367 women with newly diagnosed epithelial ovarian cancer treated with platinum-based chemotherapy, 62 (16.9%) had primary platinum-resistant ovarian cancer. The cohort had a mean age of 54 ± 11.2 years, 79% were postmenopausal, and 53.2% had Eastern Cooperative Oncology Group performance score ≥2. High-grade serous carcinoma histology predominated (75.8%), 90.3% presented with stage III to IV disease, 74.2% had ascites, and 79.1% had peritoneal spread. Debulking surgery was performed in 24.2%, platinum-taxane doublet was used in 83.9%, and among those receiving curative intent treatment, 88.1% received chemotherapy in the neoadjuvant setting. Maintenance therapy was received by 6.5%; none entered clinical trials. Over a median follow-up of 10.32 months, median progression-free and overall survival were 4.75 (95% CI, 4 to 6) and 9.33 (95% CI, 6.2 to 16.3) months, respectively, from baseline at diagnosis. Primary platinum resistance was associated with poor performance status, ascites, advanced stage, omission of debulking surgery, neoadjuvant chemotherapy, and palliative-intent chemotherapy ( P < .05). CONCLUSION Primary platinum resistance affected 16.9% of Indian women with epithelial ovarian cancer and was linked to poor performance status, advanced stage, omission of debulking surgery, neoadjuvant chemotherapy, and dismal survival outcomes underscoring the urgent need for better predictive and therapeutic strategies.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Sehrawat et al. (2026) studied this question.

synapsesocial.com/papers/6a192d4afab5b468c44161d1https://doi.org/10.1200/go-25-00650
Ask AI
Helpful
Bookmark
Share
View Full Paper